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The major human metabolic pathway for
inorganic arsenic is methylation (1–6). Most
of the inorganic arsenic, As(III) and As(V), 
is metabolized to dimethylarsinic acid
[DMA(V)] and monomethylarsonic acid
[MMA(V)] before excretion in the urine.
Because the relative acute toxicity decreases
from inorganic arsenite and arsenate [medi-
an lethal dose (LD50) 10–20 mg/kg) to
MMA(V) (LD50 700–1,600 mg/kg) and
DMA(V) (LD50 700–2,600 mg/kg), it has
been suggested that the methylation of
arsenic in the body is a detoxiﬁcation path-
way (2–6). More recent research argues that
the carcinogenic effects of these arsenic com-
pounds are not well understood and may not
follow the same decreasing order. Several
studies suggest that methylated arsenic
species, especially at the trivalent state, may
be more toxic than the parent inorganic
arsenic compounds (1,7–20). Methylation of
arsenic is also implicated in the carcinogenic
effects of arsenic because of the possible
effects on the methylation of DNA (21,22).
Methylation of arsenic involves a two-
electron reduction of pentavalent [e.g., As(V)
and MMA(V)] to trivalent [e.g., As(III) and
MMA(III)] arsenic species followed by the
transfer of a methyl group from a methyl
donor, such as S-adenosylmethionine
(23–25). The reduction and oxidative addi-
tion sequence may be summarized in Figure
1. This methylation mechanism has been
widely accepted, and the metabolites DMA(V)
and MMA(V) have been consistently observed
in human urine. A key intermediate for the
methylation of MMA(V) to DMA(V) is the
MMA(III) species. Several recent studies have
indicated the presence of MMA(III) species in
rat liver cytosol and hepatocytes and demon-
strated the important effects of the methylat-
ed trivalent arsenic species in biological
systems (16–20,26–29). Although DMA(V),
MMA(V), As(V), and inorganic As(III) have
been commonly detected in human urine
(30–43), the key intermediate metabolite
MMA(III), from the methylation of MMA(V)
to DMA(V), deserves more attention; howev-
er, there is no analytical method for the specia-
tion of MMA(III) in human systems.
This report describes the speciation of
MMA(III) in addition to the usual arsenic
species in human urine, As(III), As(V),
MMA(V), and DMA(V). Determination of
arsenic species in human urine is a measure
of recent exposure to arsenic and provides
useful information for a better understanding
of arsenic metabolism and health effects.
Materials and Methods
Reagents and standards. Sodium arsenate
[As(O)OH(ONa)2 ⋅ 7H2O] and sodium
cacodylate [(CH3)2As(O)ONa] were obtained
from Sigma (St. Louis, MO, USA), and
monomethylarsinate [CH3As(O)OHONa]
was obtained from Chem Service (West
Chester, PA, USA). Stock solutions (1,000
mg As/L) of these arsenicals were prepared by
dissolving appropriate amounts of the corre-
sponding arsenic compounds in 0.01 M
hydrocholoric acid, and standard solutions
were prepared by serial dilution with deion-
ized water. An atomic absorption arsenic stan-
dard solution (Sigma) containing 1000.0 mg
As/L as arsenite in 2% KOH was used as the
primary arsenic standard. Concentrations of
arsenic in sodium arsenate, sodium cacody-
late, and sodium monomethylarsinate solu-
tions were standardized against the atomic
absorption arsenic standard solution using
both inductively coupled plasma mass spec-
trometry (ICPMS) and ﬂame atomic absorp-
tion spectrometry analyses. The source of
MMA(III) was the solid oxide (CH3AsO),
which was prepared following the procedure
of Cullen et al. (13).
We used tetrabutylammonium hydrox-
ide as an ion-pairing reagent and malonic
acid as a buffer for HPLC separation. They
were obtained from Aldrich (Milwaukee,
WI, USA). HPLC-grade methanol was from
Fisher (Pittsburgh, PA, USA). The mobile
phase solutions (pH 5.8–5.9) containing 5
mM tetrabutylammonium hydroxide, 2–5
mM malonic acid, and 5% methanol were
prepared in deionized water and filtered
through a 0.2-µm membrane before use.
Sodium borohydride (Aldrich) solution
(1.3%) in 0.1 M sodium hydroxide (Fisher)
was prepared fresh daily. All reagents used
were of analytical grade or better.
Urine samples. One set of 164 urine sam-
ples was collected from 41 people in inner
Mongolia, China. They normally drank water
from wells containing 510–660 µg/L of
arsenic (44). All the participants were asked
not to consume seafood for 3 days before and
during the urine sample collection period.
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In this study we report on the ﬁnding of monomethylarsonous acid [MMA(III)] in human urine.
This newly identiﬁed arsenic species is a key intermediate in the metabolic pathway of arsenic
biomethylation, which involves stepwise reduction of pentavalent to trivalent arsenic species fol-
lowed by oxidative addition of a methyl group. Arsenic speciation was carried out using ion-pair
chromatographic separation of arsenic compounds with hydride generation atomic ﬂuorescence
spectrometry detection. Speciation of the inorganic arsenite [As(III)], inorganic arsenate [As(V)],
monomethylarsonic acid [MMA(V)], dimethylarsinic acid [DMA(V)], and MMA(III) in a urine
sample was complete in 5 min. Urine samples collected from humans before and after a single
oral administration of 300 mg sodium 2,3-dimercapto-1-propane sulfonate (DMPS) were ana-
lyzed for arsenic species. MMA(III) was found in 51 out of 123 urine samples collected from 41
people in inner Mongolia 0–6 hr after the administration of DMPS. MMA(III )in urine samples
did not arise from the reduction of MMA(V) by DMPS. DMPS probably assisted the release of
MMA(III) that was formed in the body. Along with the presence of MMA(III), there was an
increase in the relative concentration of MMA(V) and a decrease in DMA(V) in the urine samples
collected after the DMPS ingestion. Key words: arsenic speciation, biomarkers, metabolism,
methylation, monomethylarsonous acid, sodium 2,3-dimercapto-1-propane sulfonate, trivalent
methylarsenic species, urine metabolites. Environ Health Perspect 108:1015–1018 (2000).
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ArticlesThey fasted overnight and were then given
300 mg of sodium 2,3-dimercapto-1-propane
sulfonate (DMPS) orally. A urine sample was
collected from each person before the admin-
istration of DMPS (between 11 hr before and
the time of DMPS administration). We col-
lected three urine samples from each person
0–2 hr, 2–4 hr, and 4–6 hr after the adminis-
tration of DMPS. From the time of overnight
fast and throughout the study, the partici-
pants did not drink well water; instead, they
drank distilled water. Details on participant
selection criteria and protocols for DMPS
administration are described elsewhere (44).
Informed consent was obtained from the par-
ticipants before the study. 
Urine samples were collected in 3-L poly-
ethylene containers (Baxter Laboratories,
Inc., Morton Grove, IL, USA). Samples were
immediately frozen by placing them in a
portable icebox containing dry ice. The sam-
ples were kept frozen during transportation
and were stored at –20°C. The samples were
stored for approximately 6 months before
analysis. Samples were thawed at room tem-
perature and an aliquot was analyzed for
arsenic species using HPLC separation with
hydride generation atomic ﬂuorescence spec-
trometry (HGAFS) detection.
A Standard Reference Material (SRM),
Toxic Metals in Freeze-Dried Urine (SRM
2670), was obtained from the National
Institute of Standards and Technology
(NIST, Gaithersburg, MD, USA). The
freeze-dried urine was reconstituted by
adding 20.0 mL deionized water as recom-
mended by the supplier. The certiﬁed value
for total arsenic concentration is 480 ± 100
µg/L in two bottles containing elevated levels
of toxic metals. In the other two bottles con-
taining normal levels of toxic metals, the con-
centration of arsenic is not certiﬁed, and a
reference value of 60 µg/L has been provided.
We used the SRM for method validation.
Results for the speciation of arsenic in the
SRM using the HPLC-HGAFS method were
in good agreement with the certiﬁed and ref-
erence values (45).
Separation of arsenic using HPLC with
HGAFS detection. The method of quantify-
ing arsenic species was modiﬁed from previous
methods using ion pair chromatographic sepa-
ration with HGAFS (43,46). The HPLC sys-
tem consisted of a Gilson Model 370 pump
(Middletone, WI, USA) with a 5 mL/min
stainless steel pump head, a Rheodyne 6-port
sample injector (Model 7725i; Rheodyne,
Rohnert Park, CA, USA) with a 20-µL sample
loop, and a reversed-phase C18 column
(ODS-3, 150 mm × 4.6 mm, 3-µm particle
size; Phenomenex, Torrance, CA, USA). 
The temperature of the HPLC column
was maintained at 50°C. For temperature con-
trol, the separation column was mounted
inside a column heater (Model CH-30;
Eppendorf, Westbury, NY, USA), which was
controlled by a temperature controller (Model
TC-50; Eppendorf). The mobile phase was
preheated to the temperature of the column
by using a precolumn coil of 50-cm stainless-
steel capillary tubing, which was also placed
inside the column heater. 
A mobile-phase solution (pH 5.8–5.9)
containing 5 mM tetrabutylammonium
hydroxide, 2–5 mM malonic acid, and 5%
methanol was pumped through the column at
a ﬂow rate of 1.2–1.5 mL/min. Efﬂuent from
the HPLC column was mixed at two T-
joints, with continuous ﬂows of hydrochloric
acid (1.8 M) and sodium borohydride
(1.3%). Arsines generated were separated
from liquid waste and carried by a continuous
ﬂow of argon to an atomic ﬂuorescence detec-
tor (Excalibur 10.003; P.S. Analytical, Kent,
UK) for quantitation.
The atomic ﬂuorescence detector consist-
ed of an excitation source, an atom cell, ﬂuo-
rescence collection optics, a photomultiplier
tube, and a data collection unit. A quartz
tube with argon/hydrogen diffusion flame
was used as the atom cell for atomization. An
arsenic hollow cathode lamp was used for ﬂu-
orescence excitation. Atomic fluorescence
(193.7 nm) was collected at a right angle
with respect to the excitation light, optically
filtered with a multireflectance filter to
reduce scattering and background noise, and
detected with a solar blind photo multiplier
tube. We used a pentium computer with
Varian Star Workstation software (Victoria,
Australia) and an analog/digital converter
board to acquire and process signals from the
atomic ﬂuorescence detector. 
Results and Discussion
We have previously investigated HPLC condi-
tions and optimized them for rapid separation
of As(III), As(V), MMA(V), and DMA(V)
(46). The speciation of these four usual arsenic
compounds in urine is complete in 4 min
(Figure 2A). Within this narrow separation
time window, however, MMA(III) coelutes
with As(III) and DMA(V). To obtain a sepa-
ration of MMA(III) from As(III) and
DMA(V), an improvement in the resolution
between As(III)and DMA(V) is needed to
allow for a wider separation window
between these two species. This can be
achieved by adjusting malonic acid concen-
tration in the HPLC mobile phase. By
reducing malonic acid concentration from 5
mM (Figure 2A) to 2 mM (Figure 2B), an
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Figure 1. Summary of the reduction and oxidative addition sequence of arsenic methylation. 
Figure 2. Chromatograms showing the separation of mixtures of As(III), As(V), MMA(V), DMA(V), and
MMA(III) in deionized water. arb, arbitrary. The analyte mixtures contained As(III), As(V), MMA(V) and
DMA(V) (A, B); MMA(III) standard (C); and As(III), As(V), MMA(V), DMA(V), and MMA(III) (D). For (A), the
mobile phase contained 5 mM tetrabutylammonium hydroxide, 5 mM malonic acid, and 5% methanol (pH
5.9), and its ﬂow rate was 1.5 mL/min. For (B) and (C), the mobile phase contained 5 mM tetrabutylammo-
nium hydroxide, 2 mM malonic acid and 5% methanol (pH 5.9), and its ﬂow rate was 1.2 mL/min. For (D),
the mobile phase contained 5 mM tetrabutylammonium hydroxide, 3 mM malonic acid, and 5% methanol
(pH 5.85), and its ﬂow rate was 1.2 mL/min. Peaks labeled 1–5 correspond to As(III), MMA(III), DMA(V),
MMA(V), and As(V), respectively.
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Under these conditions, MMA(III) (Figure
2C) can be resolved from As(III) and
DMA(V). This is at the expense of a longer
retention time (6 min) for the arsenic species
(Figure 2B). To achieve a reasonable separa-
tion within the shortest time possible, we
chose to use 3 mM malonic acid in the
mobile phase. The speciation of the five
arsenic compounds, As(III), As(V), MMA(V),
DMA(V), and MMA(III), is complete in 5
min (Figure 2D). 
Figure 3 shows chromatograms from
HPLC-HGAFS analyses of a urine sample
(dotted trace) and the urine sample spiked
with MMA(III) and MMA(V) standards
(solid trace). The retention time of the sus-
pected MMA(III) in urine sample (dotted
trace) is identical to that from the authentic
MMA(III) standard. Co-injection of the
MMA(III) standard with the urine sample
(solid trace) demonstrates the co-elution of the
suspected MMA(III) peak in the sample with
that of the standard MMA(III), conﬁrming
the identity of MMA(III) in the urine sample.
The detection limit for MMA(III) in
urine is 4 µg/L. We are currently improving
this detection limit, and we expect to achieve
a detection limit of 1 µg/L.
Figure 4 shows a series of chro-
matograms from the HPLC-HGAFS analy-
ses of urine samples from a subject before
and after a single oral administration of 300
mg of DMPS. No MMA(III) is observed in
the urine sample collected before the DMPS
treatment; inorganic As(III), DMA(V), and
MMA(V) are the major arsenic species
(Figure 4A). Following the administration of
DMPS, MMA(III) is observed in all the three
samples collected between 0–2 hr (Figure
4B), 2–4 hr (Figure 4C), and 4–6 hr (Figure
4D) after the DMPS treatment. Concen-
trations of arsenic species in these samples are
summarized in Table 1. These are among the
samples that have the highest arsenic concen-
trations from a total of 164 urine samples
from 41 people in inner Mongolia (44).
Before DMPS treatment, the proportions of
inorganic As(III) (9%), MMA(V) (10%), and
DMA(V) (81%) in the urine sample are simi-
lar to those reported in literature (30,32,47).
After the DMPS treatment, the arsenic specia-
tion patterns are markedly altered. The pro-
portions of the trivalent arsenic species [As(III)
and MMA(III)] is dramatically increased to
30–40%. DMA(V) is dramatically decreased
to about 30%. MMA(V) is increased to about
30%. Most importantly, MMA(III), a key
arsenic methylation intermediate, is observed.
To examine whether the presence of
MMA(III) is due to reduction by excess
DMPS present in urine, we added 100 µg/L
MMA(V) and 100 mg/L DMPS to a urine
sample and kept the mixture at room tem-
perature for up to 48 hr. The reaction mix-
ture was periodically sampled and analyzed
using the HPLC-HGAFS method. No
MMA(III) was detected from the mixture,
although the molar concentration of DMPS
is approximately 360-fold that of MMA(V).
The concentration of DMPS in urine after a
single oral administration of DMPS is below
this level (48). The results conﬁrm that the
MMA(III) detected in urine samples of
DMPS-treated people is not simply due to
the reduction of MMA(V) to MMA(III) in
vitro. Furthermore, a reduction of MMA(V)
to MMA(III) would lead to a decreased con-
centration of MMA(V). But this is clearly
not the case, as shown in Figure 4 and Table
1. In fact, there is an increase in the relative
concentration of MMA(V) and a decrease in
DMA(V). The MMA(III) species is likely
formed in vivo. The administration of
DMPS probably assists the release of
MMA(III) from the body and the subse-
quent excretion in the urine.
We have further analyzed arsenic species
in another set of urine samples from people
in Romania (29). We also found MMA(III)
in the ﬁrst-morning-void urine samples from
10 people before DMPS treatment (29). This
conﬁrms that the presence of MMA(III) is
not due to the DMPS treatment although it
is possible that DMPS treatment may affect
arsenic metabolism.
MMA(III) can be readily oxidized to
MMA(V) during sample storage. In a prelim-
inary study of the stability of MMA(III), we
found that approximately 60% of 100 µg/L
MMA(III) spiked into a urine sample was
oxidized to MMA(V) after the sample was
stored for 2 weeks at 4°C. The samples we
Articles • Urinary speciation of MMA(III) 
Environmental Health Perspectives • VOLUME 108 | NUMBER 11 | November 2000 1017
Figure 3. Chromatograms obtained from the HPLC-
HGAFS analyses of a urine sample (dotted trace)
and the urine sample spiked with MMA(III) and
MMA(V) (solid trace). arb, arbitrary. The same
conditions as shown in Figure 2D. were used.
Peak identities are the same as shown in Figure 2. 
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Figure 4. Chromatograms obtained from the HPLC-HGAFS analyses of a series of urine samples collected
from a subject before and after a single oral dose of 300 mg DMPS (A) between 11 hr before and the time
of the DMPS administration, and (B) 0–2 hr, (C) 2–4 hr, and (D) 4–6 hr after the administration of DMPS.
The same conditions as shown in Figure 2D were used. Peak identities are the same as shown in Figure 2. 
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Table 1. Concentrations of arsenic species (µg/L) in urine samples collected from a subject before and
after the administration of 300 mg DMPS.
Sample Sampling time As(III) As(V) MMA(V) DMA(V) MMA(III) Sum
15A –11–0 hr 63 ± 1 ND 66 ± 3 564 ± 9 ND 693 ± 9
15B 0–2 hr 44 ± 1 ND 239 ± 2 250 ± 2 227 ± 5 760 ± 5
15C 2–4 hr 313 ± 9 14 ± 1 311 ± 12 329 ± 5 240 ± 4 1,202 ± 12
15D 4–6 hr 59 + 1 ND 53 ± 2 72 ± 4 43 ± 3 227 ± 4
ND, below detection limit [1 µg/L for As(V) and 4 µg/L for MMA(III)]. Results are means ± 1 SD from triplicate analyses of
each sample. used in this study had been stored at 
–20°C for 1–6 months before arsenic
speciation analyses. It is possible that the
MMA(III) we detected in these urine samples
is underestimated because of possible conver-
sion of MMA(III) to MMA(V) during the
sample storage. In our previous studies of the
stability of As(III), As(V), MMA(V), and
DMA(V), we did not observe any conversion
of these species to MMA(III) (45). 
Biomethylation is commonly assumed to
be the main process of detoxifying arsenic
(2–6) because the metabolites usually
observed in urine, MMA(V) and DMA(V),
are less acutely toxic and more readily excret-
ed in urine than the inorganic arsenic
species. However, there is evidence that
MMA(III) could be more toxic than the
inorganic arsenic species (16–18). The ﬁnd-
ing of highly toxic MMA(III) species in
human urine reported here, together with
recent studies on the toxic effects of arsenic,
suggests that methylation of arsenic may not
be strictly a detoxification process for
humans, as previously believed. Although
epidemiologic studies have demonstrated
dose–response relationships between the
exposure to high levels of arsenic (hundreds
of microgram per liter) and the prevalence of
skin, bladder, and lung cancers, health
effects resulting from lower levels of arsenic
ingestion have not been delineated (25).
Studies of arsenic metabolism should con-
tribute to a better understanding of arsenic
health effects. The technique we have devel-
oped to detect trace levels of As(III), As(V),
MMA(V), DMA(V), and MMA(III) in
human urine is useful for metabolic and epi-
demiologic studies of arsenic.
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